Compare STRIDES PHARMA SCIENCE with WYETH - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs WYETH - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

WYETH 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE WYETH STRIDES PHARMA SCIENCE/
WYETH
 
P/E (TTM) x 43.7 27.7 157.7% View Chart
P/BV x 2.0 5.3 38.2% View Chart
Dividend Yield % 0.2 1.3 18.7%  

Financials

 STRIDES PHARMA SCIENCE   WYETH
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
WYETH
Mar-13
STRIDES PHARMA SCIENCE/
WYETH
5-Yr Chart
Click to enlarge
High Rs1,1471,044 109.8%   
Low Rs642818 78.5%   
Sales per share (Unadj.) Rs317.2298.6 106.3%  
Earnings per share (Unadj.) Rs7.857.2 13.7%  
Cash flow per share (Unadj.) Rs25.158.4 42.9%  
Dividends per share (Unadj.) Rs2.0017.00 11.8%  
Dividend yield (eoy) %0.21.8 12.2%  
Book value per share (Unadj.) Rs274.3249.5 109.9%  
Shares outstanding (eoy) m89.5022.72 393.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.83.1 90.4%   
Avg P/E ratio x114.016.3 700.9%  
P/CF ratio (eoy) x35.715.9 223.9%  
Price / Book Value ratio x3.33.7 87.4%  
Dividend payout %25.529.7 85.8%   
Avg Mkt Cap Rs m80,05821,157 378.4%   
No. of employees `0002.50.5 509.6%   
Total wages/salary Rs m4,341400 1,085.1%   
Avg. sales/employee Rs Th11,325.813,787.4 82.1%   
Avg. wages/employee Rs Th1,731.4813.0 213.0%   
Avg. net profit/employee Rs Th280.12,643.3 10.6%   
INCOME DATA
Net Sales Rs m28,3946,783 418.6%  
Other income Rs m941353 266.8%   
Total revenues Rs m29,3347,136 411.1%   
Gross profit Rs m3,9651,617 245.2%  
Depreciation Rs m1,54027 5,791.0%   
Interest Rs m1,9626 35,680.0%   
Profit before tax Rs m1,4031,938 72.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-436-5 8,545.1%   
Tax Rs m97632 15.4%   
Profit after tax Rs m7021,301 54.0%  
Gross profit margin %14.023.8 58.6%  
Effective tax rate %6.932.6 21.3%   
Net profit margin %2.519.2 12.9%  
BALANCE SHEET DATA
Current assets Rs m24,8366,984 355.6%   
Current liabilities Rs m18,9932,056 923.8%   
Net working cap to sales %20.672.6 28.3%  
Current ratio x1.33.4 38.5%  
Inventory Days Days7199 71.5%  
Debtors Days Days11324 473.7%  
Net fixed assets Rs m34,289244 14,035.5%   
Share capital Rs m895227 393.9%   
"Free" reserves Rs m23,6515,441 434.7%   
Net worth Rs m24,5465,668 433.1%   
Long term debt Rs m15,51325 62,052.8%   
Total assets Rs m65,4377,901 828.2%  
Interest coverage x1.7353.3 0.5%   
Debt to equity ratio x0.60 14,329.1%  
Sales to assets ratio x0.40.9 50.5%   
Return on assets %4.116.5 24.6%  
Return on equity %2.922.9 12.5%  
Return on capital %6.934.0 20.3%  
Exports to sales %00.2 0.0%   
Imports to sales %036.3 0.0%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs mNA2,465 0.0%   
Fx inflow Rs m15,69715 103,270.4%   
Fx outflow Rs m7352,677 27.5%   
Net fx Rs m14,962-2,662 -562.0%   
CASH FLOW
From Operations Rs m1,871923 202.6%  
From Investments Rs m5,826317 1,838.4%  
From Financial Activity Rs m-10,157-481 2,111.6%  
Net Cashflow Rs m-2,615759 -344.5%  

Share Holding

Indian Promoters % 27.7 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 37.8 11.3 334.5%  
FIIs % 8.6 7.2 119.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 30.4 85.2%  
Shareholders   56,241 21,978 255.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   BIOCON   CADILA HEALTHCARE  SUVEN LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Snap 4-Day Winning Streak; JSW Steel and Hindalco Among Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


May 11, 2021 03:36 PM

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 8-QTR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS